Recent advances in radionuclide therapy

Suresh Srivastava, Ekaterina Dadachova

Research output: Contribution to journalArticle

68 Citations (Scopus)

Abstract

A variety of radionuclides continue to be investigated and/or clinically used for different therapeutic applications in nuclear medicine. The choice of a particular radionuclide with regard to appropriate emissions, linear energy transfer, and physical half-life is dictated to a large extent by the character of the disease (eg, solid tumor or metastatic disease) and by the carrier used to selectively transport the radionuclide to the desired site. An impressive body of information has appeared in the recent literature that addresses many of these considerations. This article summarizes and discusses the many recent advances and the progress in the clinical applications of therapeutic radionuclides in relatively new and developing areas, such as radioimmunotherapy, peptide therapy, intravascular therapy to prevent restenosis, radiation synovectomy, and bone malignancy therapy. Projections are made as to the future directions and progress in these areas. The crucial issue of a reliable, year-round supply of new and emerging therapeutic radionuclides in quantities sufficient initially for research, and then for routine clinical use, is a very worthy goal which, in the United States, remains to be achieved.

Original languageEnglish (US)
Pages (from-to)330-341
Number of pages12
JournalSeminars in Nuclear Medicine
Volume31
Issue number4
StatePublished - 2001

Fingerprint

Radioisotopes
Therapeutics
Radioimmunotherapy
Linear Energy Transfer
Nuclear Medicine
Half-Life
Neoplasms
Radiation
Bone and Bones
Peptides
Research

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Radiological and Ultrasound Technology

Cite this

Srivastava, S., & Dadachova, E. (2001). Recent advances in radionuclide therapy. Seminars in Nuclear Medicine, 31(4), 330-341.

Recent advances in radionuclide therapy. / Srivastava, Suresh; Dadachova, Ekaterina.

In: Seminars in Nuclear Medicine, Vol. 31, No. 4, 2001, p. 330-341.

Research output: Contribution to journalArticle

Srivastava, S & Dadachova, E 2001, 'Recent advances in radionuclide therapy', Seminars in Nuclear Medicine, vol. 31, no. 4, pp. 330-341.
Srivastava S, Dadachova E. Recent advances in radionuclide therapy. Seminars in Nuclear Medicine. 2001;31(4):330-341.
Srivastava, Suresh ; Dadachova, Ekaterina. / Recent advances in radionuclide therapy. In: Seminars in Nuclear Medicine. 2001 ; Vol. 31, No. 4. pp. 330-341.
@article{2fb86313ae0d442db0700d9546fe1329,
title = "Recent advances in radionuclide therapy",
abstract = "A variety of radionuclides continue to be investigated and/or clinically used for different therapeutic applications in nuclear medicine. The choice of a particular radionuclide with regard to appropriate emissions, linear energy transfer, and physical half-life is dictated to a large extent by the character of the disease (eg, solid tumor or metastatic disease) and by the carrier used to selectively transport the radionuclide to the desired site. An impressive body of information has appeared in the recent literature that addresses many of these considerations. This article summarizes and discusses the many recent advances and the progress in the clinical applications of therapeutic radionuclides in relatively new and developing areas, such as radioimmunotherapy, peptide therapy, intravascular therapy to prevent restenosis, radiation synovectomy, and bone malignancy therapy. Projections are made as to the future directions and progress in these areas. The crucial issue of a reliable, year-round supply of new and emerging therapeutic radionuclides in quantities sufficient initially for research, and then for routine clinical use, is a very worthy goal which, in the United States, remains to be achieved.",
author = "Suresh Srivastava and Ekaterina Dadachova",
year = "2001",
language = "English (US)",
volume = "31",
pages = "330--341",
journal = "Seminars in Nuclear Medicine",
issn = "0001-2998",
publisher = "W.B. Saunders Ltd",
number = "4",

}

TY - JOUR

T1 - Recent advances in radionuclide therapy

AU - Srivastava, Suresh

AU - Dadachova, Ekaterina

PY - 2001

Y1 - 2001

N2 - A variety of radionuclides continue to be investigated and/or clinically used for different therapeutic applications in nuclear medicine. The choice of a particular radionuclide with regard to appropriate emissions, linear energy transfer, and physical half-life is dictated to a large extent by the character of the disease (eg, solid tumor or metastatic disease) and by the carrier used to selectively transport the radionuclide to the desired site. An impressive body of information has appeared in the recent literature that addresses many of these considerations. This article summarizes and discusses the many recent advances and the progress in the clinical applications of therapeutic radionuclides in relatively new and developing areas, such as radioimmunotherapy, peptide therapy, intravascular therapy to prevent restenosis, radiation synovectomy, and bone malignancy therapy. Projections are made as to the future directions and progress in these areas. The crucial issue of a reliable, year-round supply of new and emerging therapeutic radionuclides in quantities sufficient initially for research, and then for routine clinical use, is a very worthy goal which, in the United States, remains to be achieved.

AB - A variety of radionuclides continue to be investigated and/or clinically used for different therapeutic applications in nuclear medicine. The choice of a particular radionuclide with regard to appropriate emissions, linear energy transfer, and physical half-life is dictated to a large extent by the character of the disease (eg, solid tumor or metastatic disease) and by the carrier used to selectively transport the radionuclide to the desired site. An impressive body of information has appeared in the recent literature that addresses many of these considerations. This article summarizes and discusses the many recent advances and the progress in the clinical applications of therapeutic radionuclides in relatively new and developing areas, such as radioimmunotherapy, peptide therapy, intravascular therapy to prevent restenosis, radiation synovectomy, and bone malignancy therapy. Projections are made as to the future directions and progress in these areas. The crucial issue of a reliable, year-round supply of new and emerging therapeutic radionuclides in quantities sufficient initially for research, and then for routine clinical use, is a very worthy goal which, in the United States, remains to be achieved.

UR - http://www.scopus.com/inward/record.url?scp=0034759194&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034759194&partnerID=8YFLogxK

M3 - Article

C2 - 11710775

AN - SCOPUS:0034759194

VL - 31

SP - 330

EP - 341

JO - Seminars in Nuclear Medicine

JF - Seminars in Nuclear Medicine

SN - 0001-2998

IS - 4

ER -